Figure 2. Relationship of Protease-Inhibitor Component of Antiretroviral Therapy and Total Bilirubin Levels
This graph is derived from a multivariate analysis of the contribution of protease-inhibitor components in antiretroviral therapy on patient total bilirubin levels (adjusted for age, sex, chronic hepatitis B or C, longitudinal relationship between hemoglobin and bilirubin level, and presence of UGT1A1 allelic variants associated with Gilbert's syndrome). The p value for atazanavir and indinavir was <0.0001.
From: Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381-6.
From: HIV Web Study <www.hivwebstudy.org>